Tempest Therapeutics Inc (TPST)

$2.41 -0.06 (-2.43%)
Market Cap 13.40M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 39,500
Avg Vol 134,214
Day's Range N/A - N/A
Shares Out 4.93M
Stochastic %K 7%
Beta -2.43
Analysts Strong Sell
Price Target $10.50

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Xamayca
Xamayca Feb. 4 at 1:28 AM
$TPST Is there a SEC limit to how wide the spread can be between the warrant price and the underlying stock prices so that would explain the delay? Sorry if that’s a dumb question.
0 · Reply
GreylockSec
GreylockSec Feb. 3 at 11:35 PM
$TPST ...It may a while before we get those free Warrants in our accounts. We will still need the Effective Date/Registration Statement filed with SEC to be released. Tempest News, dated 1/20/26: ..."....The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of closing conditions for the transactions contemplated by the Asset Purchase Agreement (the “Closing Conditions”), including receipt of stockholder approval of Proposal 5 contained in Tempest’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on December 31, 2025 (“Stockholder Approval”)....subject to the effectiveness of a registration statement registering the sale of the shares of common stock underlying the Warrants (the “Registration Statement”), in accordance with the terms of a warrant agreement."
2 · Reply
Xamayca
Xamayca Feb. 3 at 11:08 PM
$TPST B.P. Playing leap frog with the TPST Factor/Erigen deal and gobbling up everything at once with Angel overseeing their new acquisition hmmmm? There was nothing holding back the execution of the originally stated deal , AGM approvals, record date announced date given for warranty dividends came and went without a peep, sure feels like a superior offer seems too late stage to be a disaster ( falling apart of factor deal so I will remain optimistic but cautiously so!
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Feb. 3 at 9:02 PM
$TPST Nibbled a little today even though it looks like 1's are coming 🤷🏻‍♂️
1 · Reply
Xamayca
Xamayca Feb. 3 at 8:53 PM
$TPST I may sound a bit bi-polar but my expectations are conditioned or premised on the expectation that these guys actually complete the actions they have outlined or have a really good reason. Why they don’t)good as in positive) we are in the dark as to the lack of execution here. Delayed AGM , Faiked to fund 5mil (but excused) failed to provide warrants on the prescribed date!? Am I the only one saying WTF!?
1 · Reply
Xamayca
Xamayca Feb. 3 at 7:58 PM
$TPST Delayed AGM followed by apparent delay on issuing warrants after a record date and issuance date is provided. The only possible positive spin is the PR or events intended to accompany closing and or issuance of warrants are not yet completed, otherwise this is becoming a bonafide shit show Brady perform or forget about being chairman here and forget any other goodies you have lined up!
0 · Reply
Ueberschlaefer
Ueberschlaefer Feb. 3 at 7:50 PM
$TPST glad i sold at $5. watching this thing just sink further as i said it would... and the coping about $3... now i guess it's $2... then it will be $1... then dilution, reverse splits, wash and repeat for years on end. brady keeps his 600K salary.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 3 at 7:07 PM
$TPST MEANING, TODAY!
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 3 at 7:05 PM
$TPST If we don't get our TPST Warrants we have coming to us, then Tempest should be able to Lower the Exercise (Strike) Price in my opinion.
1 · Reply
Craynos
Craynos Feb. 3 at 6:49 PM
$TPST This has to run 500% just to break even for me. I will come back in a year a check if there is something left. Until then...f@ck the stock market, I am spending my money on travelling this year
1 · Reply
Latest News on TPST
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Jan 20, 2026, 5:20 PM EST - 14 days ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 26, 2025, 4:05 PM EST - 2 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 8:00 AM EST - 2 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nov 19, 2025, 9:00 AM EST - 2 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:30 AM EST - 3 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 6 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 8 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 8 months ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 9 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 10 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 10 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 10 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 11 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 11 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 11 months ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 9:06 AM EDT - 1 year ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Oct 10, 2023, 4:05 PM EDT - 2 years ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Tempest to Present at the Jefferies Global Healthcare Conference

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Xamayca
Xamayca Feb. 4 at 1:28 AM
$TPST Is there a SEC limit to how wide the spread can be between the warrant price and the underlying stock prices so that would explain the delay? Sorry if that’s a dumb question.
0 · Reply
GreylockSec
GreylockSec Feb. 3 at 11:35 PM
$TPST ...It may a while before we get those free Warrants in our accounts. We will still need the Effective Date/Registration Statement filed with SEC to be released. Tempest News, dated 1/20/26: ..."....The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of closing conditions for the transactions contemplated by the Asset Purchase Agreement (the “Closing Conditions”), including receipt of stockholder approval of Proposal 5 contained in Tempest’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on December 31, 2025 (“Stockholder Approval”)....subject to the effectiveness of a registration statement registering the sale of the shares of common stock underlying the Warrants (the “Registration Statement”), in accordance with the terms of a warrant agreement."
2 · Reply
Xamayca
Xamayca Feb. 3 at 11:08 PM
$TPST B.P. Playing leap frog with the TPST Factor/Erigen deal and gobbling up everything at once with Angel overseeing their new acquisition hmmmm? There was nothing holding back the execution of the originally stated deal , AGM approvals, record date announced date given for warranty dividends came and went without a peep, sure feels like a superior offer seems too late stage to be a disaster ( falling apart of factor deal so I will remain optimistic but cautiously so!
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Feb. 3 at 9:02 PM
$TPST Nibbled a little today even though it looks like 1's are coming 🤷🏻‍♂️
1 · Reply
Xamayca
Xamayca Feb. 3 at 8:53 PM
$TPST I may sound a bit bi-polar but my expectations are conditioned or premised on the expectation that these guys actually complete the actions they have outlined or have a really good reason. Why they don’t)good as in positive) we are in the dark as to the lack of execution here. Delayed AGM , Faiked to fund 5mil (but excused) failed to provide warrants on the prescribed date!? Am I the only one saying WTF!?
1 · Reply
Xamayca
Xamayca Feb. 3 at 7:58 PM
$TPST Delayed AGM followed by apparent delay on issuing warrants after a record date and issuance date is provided. The only possible positive spin is the PR or events intended to accompany closing and or issuance of warrants are not yet completed, otherwise this is becoming a bonafide shit show Brady perform or forget about being chairman here and forget any other goodies you have lined up!
0 · Reply
Ueberschlaefer
Ueberschlaefer Feb. 3 at 7:50 PM
$TPST glad i sold at $5. watching this thing just sink further as i said it would... and the coping about $3... now i guess it's $2... then it will be $1... then dilution, reverse splits, wash and repeat for years on end. brady keeps his 600K salary.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 3 at 7:07 PM
$TPST MEANING, TODAY!
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 3 at 7:05 PM
$TPST If we don't get our TPST Warrants we have coming to us, then Tempest should be able to Lower the Exercise (Strike) Price in my opinion.
1 · Reply
Craynos
Craynos Feb. 3 at 6:49 PM
$TPST This has to run 500% just to break even for me. I will come back in a year a check if there is something left. Until then...f@ck the stock market, I am spending my money on travelling this year
1 · Reply
lgb2
lgb2 Feb. 3 at 5:58 PM
$TPST scammer alert
0 · Reply
Michl2000
Michl2000 Feb. 3 at 5:45 PM
$TPST 💩💩💩
0 · Reply
YieldYeah
YieldYeah Feb. 3 at 3:31 PM
$TPST There are some seriously smart and strategic players behind this merger: Angel, Brady, MTS, and Lotus Billionaire Brothers. I'm excited to see what the coming weeks and months will hold for us. I’m betting after the Closing 8K happens, Tempest 2.0 will have a series of PR’s ready for the market to reassess the value of the company's assets. The forced silence will be over soon and things could start to get really interesting!
1 · Reply
lousjamsession
lousjamsession Feb. 3 at 3:09 PM
$TPST
1 · Reply
Xamayca
Xamayca Feb. 3 at 2:57 PM
$TPST Those selling are being robbed lol. Sorry for thinking out loud the point is something much better is in the offing! I may have to add a couple thousand here.
2 · Reply
Xamayca
Xamayca Feb. 3 at 2:42 PM
$TPST Is there not an issue of fraud! If TPST fails to make good on these warrants which think dived everybody into holding shares for in the case they do not make good
1 · Reply
JMALSH
JMALSH Feb. 3 at 2:36 PM
$TPST When will the warrents be traded?
1 · Reply
fantastex
fantastex Feb. 3 at 12:11 PM
$TPST whats the cash on hand here anybody knows?
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 3 at 6:00 AM
$TPST I recommend that if you are a Bull Buying Warrants and Shares, both, that you Buy the Warrants, first. Once you later Buy the Shares, this would help Rise Warrants Price (WP). It doesn't function as intended, trying it the other way. Buying Warrants does not directly affect Stock Price. Buying Shares DOES alter WP. Buy Warrants first, Bulls, when Buying both Warrants and Shares.
1 · Reply
Onedaytolive
Onedaytolive Feb. 3 at 4:44 AM
$TPST First of all, think about it. Why do you think that mean Sabi agreed to a $3.5 capital increase? Moreover, the risk of loss is high, and the stock price is actually $2.5. This fact itself is fundamentally strange.I've heard quite a huge story from Brady, Angel, and Fixer Lotus. It's also thanks to Sabi's nimble footwork that he can move nearly 5 million yen in a short period of time until the end of January.
0 · Reply
Onedaytolive
Onedaytolive Feb. 3 at 3:57 AM
$TPST At this point, I think we have a pretty good idea of the potential buyers. Companies that want to buy the 2003 dual CAR-T and mRNA × dual CAR-T platforms, the former TPST pipeline, and AZ's dual CAR-T with the option to crush it are probably this one, that one, and the other one. It would be even more interesting if AZ added to the price to protect its pipeline. Even if AZ does not enter the fray, the acquisition price is expected to easily exceed the $18 warrant.
1 · Reply
Onedaytolive
Onedaytolive Feb. 3 at 3:10 AM
$TPST Results of clinical trials involving 23 subjects in TPST-2003 https://ash.confex.com/ash/2024/webprogram/Paper201160.html?utm_source=chatgpt.com
2 · Reply